Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease; and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA.
Company profile
Ticker
CRXM
Exchange
Website
CEO
Christopher J. Reinhard
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ARIES VENTURES INC, Cardium Therapeutics, Inc., CASMYN CORP, Taxus Cardium Pharmaceuticals Group Inc.
SEC CIK
Corporate docs
Subsidiaries
Activation Therapeutics, Inc. • Angionetics, Inc. ...
IRS number
840635673
CRXM stock data
Latest filings (excl ownership)
10-K/A
2020 FY
Annual report (amended)
13 Apr 22
10-K
2020 FY
Annual report
30 Mar 22
10-Q
2020 Q3
Quarterly report
27 Oct 21
10-Q
2020 Q2
Quarterly report
17 Sep 21
10-Q
2020 Q1
Quarterly report
3 Sep 21
8-K/A
Changes in Registrant's Certifying Accountant
9 Aug 21
8-K
Changes in Registrant's Certifying Accountant
5 Aug 21
8-K
Gene Biotherapeutics Announces Director Retirement
28 Jul 21
8-K
Gene Biotherapeutics Partners with Fujifilm Diosynth
26 Apr 21
10-K
2019 FY
Annual report
23 Apr 21
Latest ownership filings
SC 13G/A
Jemapete Christopher J
3 Feb 23
SC 13G/A
SABBY MANAGEMENT, LLC
5 Jan 22
SC 13G
Jemapete Christopher J
28 Apr 21
4
Christopher J Jemapete
28 Apr 21
4
Christopher J Jemapete
18 Mar 21
SC 13D/A
Jemapete Christopher J
18 Mar 21
SC 13D
Jemapete Christopher J
1 Mar 21
3
Christopher J Jemapete
1 Mar 21
SC 13G
Coluccio Christian F
22 Dec 20
3
NIRMAL MULYE
17 Aug 20
Financial summary
Quarter (USD) | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 16 | Dec 15 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 386.03 k | 386.03 k | 386.03 k | 386.03 k | 386.03 k | 386.03 k |
Cash burn (monthly) | 131.85 k | (no burn) | 359.31 k | 105.18 k | 112.62 k | 94.42 k |
Cash used (since last report) | 5.24 mm | n/a | 14.29 mm | 4.18 mm | 4.48 mm | 3.76 mm |
Cash remaining | -4.86 mm | n/a | -13.91 mm | -3.80 mm | -4.09 mm | -3.37 mm |
Runway (months of cash) | -36.8 | n/a | -38.7 | -36.1 | -36.3 | -35.7 |